Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Autologous SUPLEXA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Autologous SUPLEXA overview
Cellular therapy is under development for the treatment of hematological malignancies including relapsed or refractory multiple myeloma, lymphoma, and chronic lymphocytic leukemia and solid tumors including ovarian cancer, bladder cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It is administered through intravenous route. It comprises of non-engineered autologous peripheral blood mononuclear cells, PBMC-derived cellular therapy being developed based on ENLIST cell platform.
Alloplex Biotherapeutics overview
Alloplex Biotherapeutics is developing cellular therapeutics for the treatment of tumor. The company is headquartered in Woburn, Massachusetts, the US.
For a complete picture of Autologous SUPLEXA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
